NASDAQ:BIIB • US09062X1037
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for BIOGEN INC (BIIB).
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-17 | HSBC | Maintains | Reduce -> Reduce |
| 2026-02-20 | Barclays | Initiate | Equal-Weight |
| 2026-02-10 | Wedbush | Maintains | Neutral -> Neutral |
| 2026-02-09 | TD Cowen | Maintains | Buy -> Buy |
| 2026-02-09 | Guggenheim | Maintains | Buy -> Buy |
| 2026-02-09 | BMO Capital | Maintains | Market Perform -> Market Perform |
| 2026-02-09 | RBC Capital | Maintains | Outperform -> Outperform |
| 2026-02-09 | Wedbush | Maintains | Neutral -> Neutral |
| 2026-02-09 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2026-02-09 | Truist Securities | Maintains | Hold -> Hold |
| 2026-02-09 | Canaccord Genuity | Maintains | Buy -> Buy |
| 2026-02-09 | Piper Sandler | Maintains | Neutral -> Neutral |
| 2026-02-09 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-02-09 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2026-01-30 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2026-01-27 | Citigroup | Maintains | Neutral -> Neutral |
| 2026-01-08 | Truist Securities | Maintains | Hold -> Hold |
| 2026-01-07 | Citigroup | Maintains | Neutral -> Neutral |
| 2025-12-12 | Morgan Stanley | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-10 | Wells Fargo | Maintains | Equal-Weight -> Equal-Weight |
| 2025-12-10 | HSBC | Downgrade | Hold -> Reduce |
| 2025-11-21 | Piper Sandler | Reiterate | Neutral -> Neutral |
| 2025-11-06 | Stifel | Upgrade | Hold -> Buy |
| 2025-11-03 | Bernstein | Maintains | Market Perform -> Market Perform |
| 2025-10-31 | RBC Capital | Maintains | Outperform -> Outperform |
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 9.836B -3.32% | 9.676B -1.62% | 9.891B 2.22% | 9.623B -2.71% | 9.54B -0.86% | 9.65B 1.15% | 9.724B 0.77% | 9.783B 0.61% | 9.545B -2.43% | 9.559B 0.15% | 9.338B -2.31% | |
| EBITDA YoY % growth | 2.669B -28.68% | 3.325B 24.56% | 3.572B 7.45% | 3.342B -6.45% | 3.231B -3.32% | 3.332B 3.13% | 3.304B -0.84% | 3.052B -7.63% | 3.959B 29.72% | 4.377B 10.56% | 4.838B 10.53% | |
| EBIT YoY % growth | 2.174B -32.56% | 2.651B 21.94% | 2.793B 5.32% | 2.933B 5.03% | 2.964B 1.06% | 3.071B 3.61% | 3.083B 0.39% | 3.051B -1.04% | 3.212B 5.28% | 3.33B 3.67% | 3.139B -5.74% | |
| Operating Margin | 22.11% | 27.40% | 28.23% | 30.48% | 31.07% | 31.82% | 31.71% | 31.19% | 33.65% | 34.84% | 33.62% | |
| EPS YoY % growth | 15.08 -18.27% | 16.47 9.22% | 15.29 -7.16% | 16.08 5.16% | 16.63 3.45% | 17.64 6.02% | 18.09 2.60% | 18.19 0.51% | 18.47 1.53% | 19.17 3.84% | 18.53 -3.39% |
All data in USD
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | Q1 / 27 | Q2 / 27 | Q3 / 27 | Q4 / 27 | |
|---|---|---|---|---|---|---|---|---|
| EPS Q2Q % growth | 3.13 3.62% | 4.40 -19.65% | 3.83 -20.47% | 3.41 71.39% | 4.14 32.33% | 4.40 0.02% | 4.60 20.26% | 4.62 35.47% |
| Revenue Q2Q % growth | 2.285B -6.01% | 2.442B -7.69% | 2.428B -4.21% | 2.401B 5.33% | 2.315B 1.31% | 2.413B -1.19% | 2.434B 0.25% | 2.446B 1.87% |
| EBITDA Q2Q % growth | 630.9M -26.83% | 803.1M -38.34% | 792.43M -37.80% | 915.25M -26.48% | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | 540.77M -20.36% | 799.95M -13.51% | 719.5M 3.61% | 679.74M 46.18% | 712.98M 31.85% | 729.3M -8.83% | 737.46M 2.50% | 716.04M 5.34% |
All data in USD
43 analysts have analysed BIIB and the average price target is 210.39 USD. This implies a price increase of 15.4% is expected in the next year compared to the current price of 182.31.
BIOGEN INC (BIIB) will report earnings on 2026-04-29.
The consensus EPS estimate for the next earnings of BIOGEN INC (BIIB) is 3.13 USD and the consensus revenue estimate is 2.29B USD.
The consensus rating for BIOGEN INC (BIIB) is 73.0233 / 100 . This indicates that analysts generally have a positive outlook on the stock.